Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
OLMA
vs
S&P 500
OLMA
S&P 500
Over the past 12 months, OLMA has underperformed S&P 500, delivering a return of -27% compared to S&P 500's +17% growth.
Stocks Performance
OLMA vs S&P 500
Performance Gap
OLMA vs S&P 500
Performance By Year
OLMA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Olema Pharmaceuticals Inc
Glance View
Olema Pharmaceuticals is a clinical-stage drug company focused on cancers that are driven by hormones, especially estrogen receptor-positive breast cancer. It is building medicines that block the hormone signaling pathways that help these tumors grow, rather than selling a broad mix of drugs or diagnostics. Its lead work centers on oral targeted therapies that are designed to be taken like standard pills and used alongside or after other cancer treatments. The company does not make money from approved commercial products yet. Its revenue comes mainly from research and collaboration agreements, milestone payments, and financing tied to advancing its drug pipeline through testing and development. In practice, Olema spends most of its resources on laboratory work, clinical trials, and regulatory steps needed to move a drug from early testing toward possible approval. What makes Olema different is its narrow focus on a specific cancer biology target: the estrogen receptor and related hormone pathways. That puts it in a specialized corner of biotech where success depends on proving that its compounds can work better, or in tougher-to-treat settings, than older endocrine therapies. For investors, the business is a classic drug-development model: high risk, long development timelines, and value tied to whether its pipeline can produce an approved medicine.
